Colitis
48
11
12
23
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
4 terminated out of 48 trials
85.2%
-1.4% vs benchmark
10%
5 trials in Phase 3/4
30%
7 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (48)
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Optoacoustic Detection of Inflammation Using MSOT Device
KAN-004 for Immune-Related Diarrhea or Colitis
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Intestinal Biomarker Analysis After ECP for ICI Colitis